Document:

<PAGE>

                                                                   Exhibit 10.12

                                LICENSE AGREEMENT

     This License Agreement ("Agreement"), dated October 12, 1998, is entered
into by and among J. Stuart Cumming ("JSC"), Eppington Corporation, N.V. a
Netherlands Antilles corporation ("NV"), Medevec Licensing, B.V., a Netherlands
corporation ("BV"), and Medevec Supplies, Ltd., an Irish corporation
("Licensee"). NV and BV shall be hereinafter collectively referred to as
"Licensors."

                                    Recitals

     A. Licensors each hold certain rights to the Licensed Patents and Licensed
Technology defined below and Licensee desires to obtain exclusive worldwide
rights to such Licensed Patents and Licensed Technology for commercialization
and development of Licensed Products as defined below.

     B. JSC as inventor and consultant to BV has previously developed certain
technology on behalf of BV and assigned to NV and BV the rights to certain
patents more fully described in Exhibit A attached hereto.

     C. The license agreement dated October 23, 1995 by and between BV and
Licensee including all addendums thereto are hereby amended and restated in
their entirety by the terms of this Agreement.

NOW THEREFORE, the parties agree as follows:

                                    Agreement

     1. Definitions. The following capitalized terms used in this Agreement
shall mean:

          A. "Affiliate" means as to any person or entity, the possession of the
power to direct or cause the direction of the management and the policies of an
entity whether through ownership directly or indirectly of fifty percent (50%)
or more of the stock entitled to vote, and for non-stock organizations, the
right to receive fifty percent (50%) or more of the profits by contract or
otherwise, or in countries where control of fifty percent (50%) or more of such
rights is not permitted in the country where such entity exists, the maximum
permitted in such country.

          B. "Effective Date" means the date set forth on page 1, line 1, of
this Agreement.

          C. "Know-How" means unpatented and/or unpatentable technical
information, including ideas, concepts, documentation, inventions, discoveries,
data, designs, formulas, specifications, procedures for experiments and tests
and other protocols, and results of experimentation and testing, licensed by
Licensors during the term of the Agreement which are useful for the practice of
the Licensed Patents and which Licensors have the right to sublicense. Know-How
shall not include the Licensed Patents. All Know-How shall be Confidential
Information of Licensors.

<PAGE>

          D. "Licensed Patents" means the patents and patent applications owned
by Licensors and JSC including those listed on Exhibit B attached hereto,
including all divisions, continuations, continuations-in-part, foreign
counterparts, and any valid patents which may issue from the patent applications
and any reissues, renewals, substitutions, or extensions of or to any such
patents or patent applications. Licensed Patents shall not include the patent
application identified as "The apparatus and method for corneal keratotomy,
docket number 5764" and any resulting patents.

          E. "Licensed Technology" means the Licensed Patents and Know-How.

          F. "Licensed Product" means any product, device, process or method
incorporating or using any Licensed Technology or Licensed Patents.

          G. "Net Sales" means the gross amounts received by Licensee and its
Affiliates and Sublicensees for sales of Licensed Products, less the following
amounts directly chargeable to such Licensed Products: (a) customary trade,
quantity or cash discounts and rebates, actually allowed and taken; (b) amounts
repaid or credited to customers on account of rejections; (c) freight and other
transportation costs, including insurance charges, and duties, tariffs, sales
and excise taxes and other governmental charges based directly on sales,
turnover or delivery of such Licensed Products and actually paid or allowed by
Licensee and its Affiliates or any Sublicensee; and (d) amounts allowed or
credited due to returns or uncollectible amounts.

          H. "Royalties" means all amounts payable under Paragraph 3. B. of this
Agreement.

          I. "Sublicensee" means any person, company or other entity granted a
sublicense by Licensee under Paragraph 2. B. below, including Affiliates of the
Sublicensee.

          J. "Sublicense" means the license agreement entered into by Licensee
with a Sublicensee under Paragraph 2. B. below.

          K. "Territory" means worldwide.

          L. "Valid Claim" means an issued claim of any unexpired patent or a
claim of any pending patent application within the Licensed Patents which has
not been held unenforceable, unpatentable or invalid by a decision of a court or
governmental body of competent jurisdiction, in a ruling that is unappealable or
unappealed within the time allowed for appeal which has not been rendered
unenforceable through disclaimer or otherwise, and which has not been lost
through an interference proceeding. Notwithstanding the foregoing, a claim of a
pending patent application shall cease to be a Valid Claim if no patent has
issued on such claim on or prior to the fourth anniversary of the date of filing
of the corresponding parent patent application, provided that such claim shall
once again become a Valid Claim on the issue date of a patent that subsequently
issues and covers such claim.

                                      -2-

<PAGE>

     2. Grant of License

          A. Grant. Licensors hereby grant to Licensee and its Affiliates an
exclusive, worldwide irrevocable license, with a right to sublicense, under the
Licensed Patents and the Licensed Technology to make, have made, use, import,
have imported, market, offer to sell and sell Licensed Products within the
Territory.

          B. Sublicense. Licensee shall have the exclusive right to grant
sublicenses to third parties to all of the rights granted Licensee under
Paragraph 2. A on terms not in conflict with the terms of this Agreement.

          C. Enhancements. In the event that, during the term of this Agreement,
JSC or any of the Licensors develop enhancements, modifications and improvements
to any of the Licensed Technology or Licensed Patents, JSC or the Licensors, as
the case may be, shall promptly deliver all Know-How relating to such
enhancements, modifications and improvements to the Licensee, and such Know-How
shall be included in the license granted by the Licensors to the Licensee
pursuant to Paragraph 2.A above.

     3. Royalties

          A. Amount and Application.

               (1) Subject to reduction pursuant to Paragraphs 3.A.(3), (4),
(5), (6) and (7) and 7.C.(3) below, Licensee shall pay a royalty to BV during
the term of this Agreement equal to five percent (5%) of Net Sales by Licensee
or any Sublicensee of Licensed Products within the scope of a Valid Claim in the
country of manufacture or sale.

               (2) In any event no Royalty shall accrue or be payable for a
period of three (3) years from the date of this Agreement.

               (3) In the event that Licensee enters into a license agreement
with any third party with respect to intellectual property rights which are
necessary or useful for Licensee's practice of the Licensed Patents or the
manufacture, use, import and/or sale of any Licensed Product, Licensee may
offset any payments made in accordance with such license agreements against any
amounts owed Licensors pursuant to Paragraph 3 herein, up to a maximum of fifty
percent (50%) of the amounts due under Paragraph 3.

               (4) No Royalties shall be due on Licensed Products distributed
for use in research and/or development, in clinical trials or as promotional
samples.

                                       -3-
<PAGE>

               (5) No more than one Royalty payment shall be due with respect to
a sale of a particular Licensed Product. No multiple Royalties shall be payable
because any Licensed Product, or its manufacture, sale or use is covered by more
than one Valid Claim.

               (6) Royalties due under this Paragraph 3.A. shall be payable on a
country-by-country and Licensed Product-by-Licensed Product basis until the
expiration of the last-to-expire issued Valid Claim covering such Licensed
Product in such country, or if no such patent has issued in a country, until
there are no remaining pending Valid Claims covering such Licensed Product in
such country.

               (7) Nothwithstanding the provisions of Section 3.5 and 3.6(a), no
royalty shall accrue pursuant to Paragraph 3.A(1) on Net Sales attributable to
the fixed VS2 intraocular lens and inserting devices or the manufacturing
process of the fixed VS2 intraocular lenses unless and until C & C Vision, Inc.
as a sublicense under this Agreement, has received, pursuant to a sublicense,
aggregate consideration of $2,000,000 consisting of cash, property or any
combination thereof; provided that such Net Sales are not attributable in whole
or in part to accommodating lens technology related to either the VS2
intraocular lens and inserting devices or the manufacturing process of the VS2
intraocular lens.

          B. Calculation of Royalties. Royalties shall be payable in U.S.
currency within ninety (90) days after the end of each calendar quarter for the
term specified in Paragraph 8. below, beginning with the calendar quarter in
which the first commercial sale of a Licensed Product occurs which shall in no
event be prior to the date which is three (3) years from the date of this
Agreement. Each payment shall be accompanied by a statement showing Net Sales
for each country in the Territory and calculation of the Royalties due. All such
statements shall be deemed to be Confidential Information of Licensee. There
shall be deducted from all such payments taxes required to be withheld by any
governmental authority and Licensee shall provide copies of receipts for such
taxes to BV along with each royalty payment. Any necessary conversion of
currency into United States dollars shall be at the applicable rate of exchange
of Citibank, N.A., in New York, New York, on the last day of the calendar
quarter in which such transaction occurred. Payments which are delayed beyond
the ninety (90) days after the end of the quarter in which they become due shall
bear interest at a rate equal to the prime rate as reported by Chase Manhattan
Bank, New York, calculated on the number of days such payment is delinquent. If
at any time legal restrictions prevent the prompt remittance of any Royalties
owed on Net Sales in any jurisdiction, Licensee may notify BV and make such
payments by depositing the amount thereof in local currency in a bank account or
other depository in such country in the name of BV, and Licensee shall have no
further obligations including any interest obligations under this Agreement with
respect thereto.

          C. Records. Licensee shall keep, and shall cause its Affiliates and
Sublicensees of either, to keep, full and accurate books and records in
sufficient detail so that sums due BV hereunder can be properly calculated. Such
books and records shall be maintained for at least three (3) years after the
Royalty reporting period(s) to which they relate. During the term hereof and for
three (3) calendar years thereafter, Licensee shall permit, and shall cause its
Affiliates to permit, and

                                       -4-

<PAGE>

use reasonable efforts to have its Sublicensees permit certified independent
accountants designated by BV, to whom Licensee has no reasonable objection, to
examine its books and records solely for the purpose of verifying the accuracy
of the written statements submitted by Licensee and sums paid or payable. BV
may conduct such examination no more than once in any calendar year and conduct
no more than one audit of any period. After completion of any such examination,
BV shall promptly notify Licensee in writing of any proposed modification to
Licensee's statement of sums due and payable. If Licensee accepts such
modification, or if the parties agree on other modifications, one party shall
promptly pay or credit the other in accordance with such resolution. Such
examination shall be made at the expense of BV, except that if such examination
discloses a discrepancy of ten percent (10%) or more in the amount of Royalties
and other payments due BV, then Licensee shall reimburse BV for the cost of such
examination.

     4. Prosecution and Maintenance of Patents

          A. Prosecution and Maintenance.

               (1) Licensee shall be responsible for the filing, preparation,
registration, prosecution and maintenance of the Licensed Patents including all
fees and expenses related thereto. Licensee shall select patent counsel for
maintenance of all patent applications and patents within the Licensed Patents.

               (2) Licensors agree to cooperate, and agree to cause their
Affiliates to cooperate, with Licensee in the preparation, filing, prosecution
and maintenance of the Licensed Patents by disclosing such information as may be
necessary for the same and by promptly executing such documents as Licensee may
reasonably request in connection therewith. Licensors and their Affiliates shall
bear their own costs in connection with their cooperation with Licensee under
this Paragraph.

     5. Warranties: Indemnification, Insurance

          A. Licensors. The Licensors represent and warrant, that; (i) they have
the full, right, power and authority to grant the licenses to Licensee herein,
(ii) they own all right title and interest in the Licensed Patents and the
Licensed Technology, as indicated on the Exhibits hereto, and (iii) the Licensed
Patents and the Licensed Technology constitute all patents, patent applications,
techniques, inventions, practices, procedures, knowledge, data and other
intellectual property rights, relating to the use, manufacture, production and
formulation of the proprietary intraocular lens technology related in any way to
intraocular lenses which is in existence, or is in development by any of JSC
and/or the Licensors, as of the date hereof.

          B. JCS. JCS represents and warrants that: (i) the Licensed Patents are
free and clear of any lien, encumbrance, security interest or restriction on
license; (ii) when executed and delivered, this Agreement will become valid and
binding on JCS and enforceable against JCS in accordance with its terms; (iii)
he has not previously granted, and will not grant during the term of this
Agreement, any right, license or interest in and to the Licensed Patents, or any
portion thereof,

                                       -5-

<PAGE>

inconsistent with the license granted to Licensee herein; (iv) the Licensed
Patents are free and clear of any lien, encumbrance, security interest or
restriction on license; (v) there are no threatened or pending actions, suits,
investigations, claims or proceedings in any way relating to the Licensed
Patents; and (vi) as of the date of this Agreement, he has assigned to NV and/or
BV all of the patents and patent applications owned by him that relate in any
way to intraocular lenses including all divisions, continuations,
continuations-in-part, foreign counterparts and any reissues renewals,
substitutions or extensions of or to any such patents or patent applications.

          C. NV. NV represents and warrants that: (i) it is a corporation duly
organized validly existing and in good standing under the laws of the
Netherlands Antilles; (ii) when executed and delivered, this Agreement will
become valid and binding on NV and enforceable against NV in accordance with its
terms; (iii) the execution, delivery and performance of this Agreement have been
duly authorized by all necessary corporate action on the part of NV; (iv) it had
the right to grant the rights and licenses relating to the Licensed Patents
previously granted to BV; (v) the Licensed Patents are free and clear of any
lien, encumbrance, security interest or restriction on license; (vi) it has not
previously granted, and will not grant during the term of this Agreement, any
right, license or interest in and to the Licensed Patents, or any portion
thereof, inconsistent with the license granted to Licensee herein; and (vii)
there are no threatened or pending actions, suits, investigations, claims or
proceedings in any way relating to the Licensed Patents.

          D. BV. BV represents and warrants that: (i) it is a corporation duly
organized validly existing and in good standing under the laws of the
Netherlands; (ii) when executed and delivered, this Agreement will become valid
and binding on BV and enforceable against BV in accordance with its terms; (iii)
the execution, delivery and performance of this Agreement have been duly
authorized by all necessary corporate action on the part of BV; (iv) it had the
right to grant the rights and licenses relating to the Licensed Patents
previously granted to Licensee; (v) the Licensed Patents are free and clear of
any lien, encumbrance, security interest or restriction on license; (vi) it has
not previously granted, and will not grant during the term of this Agreement,
any right, license or interest in and to the Licensed Patents, or any portion
thereof, inconsistent with the license granted to Licensee herein; and (vii)
there are no threatened or pending actions, suits, investigations, claims or
proceedings in any way relating to the Licensed Patents.

          E. Licensee. Licensee represents and warrants that: (i) it is a
corporation duly organized validly existing and in good standing under the laws
of Ireland; (ii) when executed and delivered, this Agreement will become valid
and binding on Licensee and enforceable against Licensee in accordance with its
terms; (iii) the execution, delivery and performance of this Agreement have been
duly authorized by all necessary corporate action on the part of Licensee.

          F. Indemnification.

               (1) Licensee. Licensee shall indemnify, defend and hold harmless
Licensors and their directors, officers, employees and agents (each a "Licensor
Indemnitee") from and against any and all liabilities, damages, losses, costs or
expenses (including reasonable attorneys' and professional fees and other
expenses of litigation and/or arbitration) (a "Liability") resulting

                                       -6-

<PAGE>

from any claim, suit or proceeding brought by a third party against a Licensor
Indemnitee, arising out of or in connection with any misrepresentation with
regard to, or breach of, any of the representations and warranties of Licensee
set forth in Paragraph 5.E., except to the extent due to the negligence or
wilful misconduct of Licensors.

               (2) Licensors. Licensors, jointly and severally, shall indemnify,
defend and hold harmless Licensee and its directors, officers, employees and
agents (each a "Licensee Indemnitee") from and against any and all liabilities,
damages, losses, costs or expenses (including reasonable attorneys' and
professional fees and other expenses of litigation and/or arbitration) (a
"Liability") resulting from any claim, suit or proceeding brought by a third
party against a Licensee Indemnitee, arising out of or in connection with any
misrepresentation with regard to, or breach of, any of the representations and
warranties of Licensors set forth in Paragraphs A through D, except, to the
extent due to the negligence or wilful misconduct of Licensee.

               (3) Procedure. In the event that any Indemnitee intends to claim
indemnification under this Paragraph 5.F. it shall promptly notify the other
party in writing of such alleged Liability. The indemnifying party shall have
the right to control the defense thereof. The affected Indemnitees shall
cooperate fully with the indemnifying party and its legal representatives in the
investigation and conduct of any Liability covered by this Paragraph 5.F. The
Indemnitee shall not, except at its own cost, voluntarily make any payment or
incur any expense with respect to any claim, suit or Liability, or make any
admission of liability or attempt to settle any claim without the prior written
consent of the indemnifying party, which such party shall not be required to
give.

          G. Insurance. At such time as any product, process or service relating
to, or developed pursuant to this Agreement is being commercially distributed or
sold (other than for the purpose of obtaining regulatory approvals) by Licensee
or by a Sublicensee or agent of Licensee, Licensee shall, at its sole cost and
expense, procure and maintain policies of comprehensive general liability
insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual
aggregate and naming the Licensor Indemnitees as additional insureds. Such
comprehensive general liability insurance shall provide (a) product liability
coverage, and (b) broad form contractual liability coverage for Licensee's
indemnification under Paragraph 5.E. of this Agreement. If Licensee elects to
self-insure all or part of the limits described above (including deductibles or
retentions which are in excess of $250,000 annual aggregate), such
self-insurance program must be reasonably acceptable to the Licensors. The
minimum amounts of insurance coverage required under these provisions shall not
be construed to create a limit of Licensee's liability with respect to its
indemnification obligation under Paragraph 5.E of this Agreement. Licensee shall
provide any Licensor with written evidence of such insurance upon written
request of such Licensor. Licensee shall provide each of the Licensors with
written notice at least fifteen (15) days prior to the cancellation, non-renewal
or material change in such insurance. Licensee shall maintain such comprehensive
general liability insurance beyond the expiration or termination of this
Agreement during the period that any product, process, or service, relating to,
or developed pursuant to, this Agreement is being commercially distributed or
sold (other than for the purpose of obtaining regulatory approvals) by Licensee
or by a Sublicensee or agent of Licensee.

                                       -7-

<PAGE>

     6. Confidentiality.

          A. Confidentiality, Publications and Data Access. All information
submitted by one party to the other concerning the invention(s) claimed in the
Licensed Patents, Licensed Technology and Licensed Products identified as
confidential at the time of disclosure shall be considered as confidential
("Confidential Information") and shall be utilized only pursuant to the licenses
granted hereunder. During the term of this Agreement and for a period of ten
(10) years thereafter, no party shall disclose to any third party any
Confidential Information received from any other party without the specific
written consent of such party. The foregoing shall not apply where such
Confidential Information a) was or becomes public through no fault of the
receiving party, b) was, at the time of receipt, already in the possession of
receiving party as evidenced by its prior written records, c) was obtained from
a third party legally entitled to use and disclose the same, d) is independently
developed by the receiving party without use of any Confidential Information of
the disclosing party, or e) is required by law to be disclosed to a court or
governmental agency.

          B. Permitted Use and Disclosures. Notwithstanding Paragraph 6.A.
above, each party hereto may use or disclose information disclosed to it by any
other party to the extent such use or disclosure is reasonably necessary in
filing or prosecuting patent applications, prosecuting or defending litigation,
complying with applicable governmental regulations or otherwise submitting
information to tax or other governmental authorities, conducting clinical
trials, or making a permitted sublicense or otherwise exercising its rights
hereunder, provided that if a party is required to make any such disclosure of
another party's confidential information, other than pursuant to a
confidentiality agreement, it will give reasonable advance notice to the latter
party of such disclosure and, save to the extent inappropriate in the case of
patent applications, will use its best efforts to secure confidential treatment
of such information prior to its disclosure (whether through protective orders
or otherwise).

          C. Confidential Terms. Except as expressly provided herein, each party
agrees not to disclose any terms of this Agreement to any third party without
the consent of the other parties; provided, disclosures may be made as required
by securities or other applicable laws, or to actual or prospective investors or
corporate partners, or to a party's accountants, attorneys and other
professional advisors.

          D. Publications. Licensors shall provide to Licensee copies of any
proposed written publication by Licensors containing any Confidential
Information and, to the extent Licensors are aware of them, proposed
publications containing any information relating to the Licensed Patents.
Licensee agrees to provide copies of any proposed written publication of
Licensee, its Sublicensees and Affiliates of either of them to Licensors. The
parties shall provide copies of such proposed written publications at least
ninety (90) days in advance of publication. In addition, the topic and contents
of any proposed oral disclosures regarding the Licensed Patents which will be
made to third persons by Licensors shall be disclosed in writing to Licensee at
least thirty (30) days prior to any proposed oral presentation. The receiving
party may object to such proposed publication or disclosure on the grounds that
(i) it contains patentable subject matter that needs patent protection or (ii)
that the publication contains Confidential Information of the objecting party.
At the request of

                                       -8-

<PAGE>

the objecting party, Confidential Information of such party shall be deleted
from the publication or oral disclosure.

     7. Infringement. In the event of an infringement of a Licensed Patent the
following shall apply:

          A. Notice. Each party shall give the others written notice if one of
them becomes aware of any infringement by a third party of any Licensed Patent.
Upon notice of any such infringement, the parties shall promptly consult with
one another with a view toward reaching agreement on a course of action to be
pursued.

          B. Licensee's Right to Bring Infringement Action.

               (1) If a third party infringes any patent included in the
Licensed Patents, Licensee and any Sublicense shall have the right, but not the
obligation, to institute and prosecute an action or proceeding to abate such
infringement and to resolve such matter by settlement or otherwise. Licensee
shall be responsible for all costs and expenses of any action or proceeding
against infringers which Licensee initiates. Licensors shall cooperate fully in
such action, including without limitation, by joining as a party plaintiff if
required to do so by law to maintain such action or proceeding, and by executing
and making available such documents as Licensee may reasonably request. Licensee
agrees to promptly reimburse Licensors for its reasonable third party
out-of-pocket fees and expenses incurred in joining an action or proceeding or
cooperating with Licensee. Licensors may be represented by counsel in any such
legal proceedings, at Licensors' own expense, acting in an advisory but not
controlling capacity.

               (2) The prosecution, settlement, or abandonment of any action or
proceeding under Paragraph 7.B. shall be at Licensee's reasonable discretion
provided that Licensee shall not have any right to surrender any of Licensors'
rights to the Licensed Patents without the Consent of the Licensors.

               (3) Except as provided herein, all amounts of every kind and
nature recovered from an action or proceeding of infringement by Licensee shall
belong to Licensee. After deduction of the fees and expenses of both parties to
this Agreement, any remaining amounts recovered shall be considered Net Sales
under this Agreement and subject to Royalty payments in accordance with
Paragraph 3.

          C. Infringement Defense.

               (1) If any party, or any Sublicensee of Licensee, receives notice
of any claim that the manufacture, use or sale of a Licensed Product infringes
the rights of a third party, such party shall promptly give notice to the other
parties. As soon as practicable after receipt or giving of such notice Licensee
(or, at the election of the Licensee, any Sublicensee) shall defend, institute,
prosecute and control any action or proceeding with respect to such
infringement.

                                       -9-
<PAGE>

               (2) The settlement or abandonment of any action or proceeding
under Paragraph 7.C shall be at Licensee's reasonable discretion, including,
without limitation, procuring for Licensee (and any Sublicensee) the right to
continue using the infringing Licensed Patent or Licensed Technology, or
replacing or modifying the Licensed Product so that it becomes non-infringing,
provided that Licensee shall not have any right to surrender any of Licensors'
rights to the Licensed Patents without the consent of the Licensors.

               (3) Licensee (and any Sublicensee) may deduct such reasonable
expenses and costs incurred in connection with defending such infringement
action or proceeding, or incurred in connection with the claims of infringement
from any Royalties payable to the Licensors hereunder, including reasonable
attorney's fees, in connection with such suit, until such time as such expenses
have been fully reimbursed; provided, that in deducting such reasonable expenses
and costs, the Licensee (and any Sublicensee) shall only deduct up to a maximum
of fifty percent (50%) of the amounts due under Paragraph 3 hereof.

     8. Term and Expiration. Unless terminated earlier, this Agreement shall
expire on the expiration date of the last to expire of the Licensed Patents. The
term of this Agreement shall commence on the Effective Date, and unless earlier
terminated as provided herein, shall continue in full force and effect on a
country-by-country and Licensed Product-by-Licensed Product basis until there
are no remaining Royalty payment obligations in a country, at which time the
Agreement shall expire in its entirety in such country. After expiration,
Licensee may continue to use the Licensed Technology without any obligation to
pay Royalties.

     9. Arbitration. If the parties cannot satisfactorily settle any claim,
disagreement or controversy arising out of or related to this Agreement or its
interpretation, performance, nonperformance, breach or their respective rights
and obligations hereunder, such disagreement shall, at the request of either
party, be settled by arbitration as follows:

          A. Panel. All such disputes shall be referred to an arbitration panel
comprised of three persons. The arbitrators shall be persons involved in and
familiar with the licensing and technology transfer field. The arbitration shall
be held as soon as is reasonably possible after selection of the arbitration
panel. The proceedings shall be held in an informal manner as reasonably
determined by the arbitrators. Except for the right of appeal as set forth in
Paragraph 9.B. below, the parties shall be bound by a decision of the
arbitration panel with respect to the matter in dispute. All proceedings of the
arbitration panel shall be held in Orange County, California.

          B. Appeals. There shall be no appeal from an arbitration panel's
unanimous decision. In the event of a majority decision by the arbitration
panel, a dissatisfied party may appeal the panel's decision to the American
Arbitration Association (AAA) for an independent, final, binding decision. All
appeals shall be heard in Orange County, California. The dissatisfied party must
make such an appeal within thirty (30) days after receipt of the arbitration
panel's decision and if it loses the appeal must bear the parties' expenses and
costs for such appeal. The AAA is hereby authorized to make arrangements for
such appeal, to be held under the procedures provided by its arbitration rules.
Judgment upon any award rendered by all or a majority of the appeal arbitrators
or

                                      -10-

<PAGE>

a unanimous judgment of the initial panel, may be entered in any court of
competent jurisdiction, after any and all applicable appeal periods have passed.

     10. Miscellaneous

          A. Marking. Licensee shall and agrees to cause its Sublicensees and
Affiliates of either, to place in a conspicuous location on Licensed Product (or
its packaging where marking the Product is physically impossible) sold to third
parties, a patent notice in accordance with the laws concerning the marking of
patented articles in the country in which such articles are sold.

          B. United States Manufacture. Licensee agrees that, to the extent
required by 35 United States Code Section 204, any Licensed Products sold in the
United States will be manufactured substantially in the United States of
America.

          C. Export Regulations. To the extent that the United States Export
Control Regulations are applicable, neither Licensee nor Licensors shall,
without having first fully complied with such regulations, (i) knowingly
transfer, directly or indirectly, any unpublished technical data obtained or to
be obtained from the other party hereto to a destination outside the United
States, or (ii) knowingly ship, directly or indirectly, any product produced
using such unpublished technical data to any destination outside the United
States.

          D. Entire Agreement, Amendment, Waiver. This Agreement together with
the Exhibits attached hereto constitutes the entire agreement between the
parties regarding the subject matter hereof, and supersedes all prior written or
oral agreements or understandings (express or implied) between them concerning
the same subject matter. This Agreement may not be amended or modified except in
a writing signed by duly authorized representatives of each party. No waiver of
any default hereunder by any party or any failure to enforce any rights
hereunder shall be deemed to constitute a waiver of any subsequent default with
respect to the same or any other provision hereof.

          E. Notice. Any notice required or otherwise made pursuant to this
Agreement shall be in writing, sent by registered or certified mail properly
addressed, or by facsimile with confirmed answer-back, to the other party at the
address set forth below or at such other address as may be designated by written
notice to the other parties. Notice shall be deemed effective three (3) business
days following the date of sending such notice if by mail, on the day following
deposit with an overnight courier, if sent by overnight courier, or upon
confirmed answer-back if by facsimile.

                                      -11-

<PAGE>
          F. Assignment. This Agreement shall be binding on the parties hereto
and upon their respective successors and assigns. No party may assign or
delegate to a successor any of its rights and obligations hereunder without the
express written consent of the other parties hereto.

          G. Governing Law. The interpretation and performance of this Agreement
shall be governed by the laws of the State of California applicable to contracts
made and to be fully performed in that state.

          H. Advertising. Each party agrees not to use the name of the other
parties in any commercial activity, marketing, advertising or sales brochures
except with the prior written consent of the other party, which consent may be
granted or withheld in such party's sole discretion.

          I. Independent Contractors. The relationship of the parties hereto is
that of independent contractors. The parties hereto are not deemed to be agents,
partners or joint venturers of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

          J. Right to Develop Independently. Nothing in this Agreement will
impair Licensee's right to independently acquire, license, develop for itself,
or have others develop for it, intellectual property and technology performing
similar functions as the Licensed Patents or to market and distribute Licensed
Products or other products based on such other intellectual property and
technology.

                                      -12-

<PAGE>

          K. Force Majeure. No party shall lose any rights hereunder or be
liable to the other party for damages or losses (except for payment obligations)
on account of failure of performance by the defaulting party if the failure is
occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, failure of suppliers, or
any other reason where failure to perform is beyond the reasonable control and
not caused by the negligence, intentional conduct or misconduct of the
nonperforming party and the non-performing party has exerted all reasonable
efforts to avoid or remedy such force majeure; provided, however, that in no
event shall a party be required to settle any labor dispute or disturbance.

          L. Joint Action of Licensors. Any action taken by any Licensor
hereunder shall be taken as an action by Licensors jointly, and at Licensee's
request, Licensors shall provide to Licensee a written statement signed by all
Licensors, or their successors in interest, providing confirmation of such joint
action.

          M. LIMITATION OF LIABILITY. NO PARTY SHALL BE LIABLE TO ANY OTHER
PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT
OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

          N. Further Assurances. At any time or from time to time on and after
the date of this Agreement, Licensors and each of them shall at the request of
Licensee (i) deliver to Licensee such records, data or other documents
consistent with the provisions of this Agreement, (ii) execute, and deliver or
cause to be delivered, all such consents, documents or further instruments of
transfer or license, and (iii) take or cause to be taken all such actions, as
Licensee may reasonably deem necessary or desirable in order for Licensee to
obtain the full benefits of this Agreement and the transactions contemplated
hereby.

          O. Severability. In the event that any provisions of this Agreement
are determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and
effect without said provision. The parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the parties in entering this
Agreement.

          P. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and which together shall
constitute one instrument.

                                      -13-

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this agreement to be
executed by their respective duly authorized officers or representatives on the
date first above written.

J. Stuart Cumming                       Eppington Corporation, N.V.

/s/ J. Stuart Cumming                   By: /s/ Illegible
-------------------------------------       ------------------------------------
                                        Its: Illegible

Medevec Licensing, B.V.                 Medevec Supplies, Ltd.

By: /s/ Illegible                       By: /s/ Illegible
    ---------------------------------       ------------------------------------
Its: Illegible                          Its: DIRECTOR

                                      -14-

<PAGE>

                              MEDEVEC SUPPLIES LTD.

                      FIRST AMENDMENT TO LICENSE AGREEMENT

     This First Amendment to License Agreement (the "Amendment"), effective as
of May 31, 2000 (the "Effective Date"), is entered into by and among J. Stuart
Cumming ("JSC"), Eppington Corporation, N.V., a Netherlands Antilles corporation
("NV"), Medevec Licensing, B.V., a Netherlands corporation ("BV") and Medevec
Supplies, Ltd., an Irish corporation ("Licensee"). NV and BV shall be
hereinafter collectively referred to as "Licensors."

                                    RECITALS

     A. JSC, Licensors and Licensee have entered into a License Agreement date
as of October 12,1998 (the "License Agreement").

     B. JSC, Licensors and Licensee desire to amend License Agreement solely to
the extent set forth herein.

     NOW, THEREFORE, in consideration of the promises and the mutual covenants
hereinafter recited, the parties agree as follows:

     1. Amendment of License Agreement. JSC, Licensee and Licensors hereby
acknowledge and agree that the License Agreement shall be amended as follows:

          a. Paragraph 1.C of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               1.C "Know-How" means unpatented and/or unpatentable technical
          information, including ideas, concepts, documentation, inventions,
          discoveries, data, designs, formulas, specifications, MANUFACTURING
          PROCESSES AND TECHNIQUES, DRAWINGS, procedures for experiments and
          tests and other protocols, and results of experimentation and testing,
          licensed by Licensors during the term of the Agreement which are
          useful for the practice, FILING, PREPARATION, REGISTRATION,
          PROSECUTION AND MAINTENANCE of the Licensed Patents and which
          Licensors have the right to sublicense. Know-How shall not include the
          Licensed Patents. All Know-How shall be Confidential Information of
          Licensors.

          b. Paragraph 1.D of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               l.D. "Licensed Patents" means the patents and patent applications
          PREVIOUSLY OWNED BY JSC AND TRANSFERRED AND ASSIGNED TO, AND CURRENTLY
          owned

<PAGE>

          by Licensors including those listed on Exhibit B attached hereto,
          including all divisions, continuations, continuations-in-part, foreign
          counterparts, and any valid patents which may issue from the patent
          applications and any reissues, renewals, substitutions, or extensions
          of or to any such patents or patent applications. Licensed Patents
          shall not include the patent application identified as "The apparatus
          and method for corneal keratotomy, docket number 5764 and any
          resulting patents.

          c. Paragraph 2.C of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               2.C Enhancements. In the event that, during the term of this
          Agreement, JSC or any of the Licensors develop enhancements,
          modifications and improvements to any of the Licensed Technology or
          Licensed Patents, JSC or the Licensors, as the case may be, shall
          promptly NOTIFY LICENSEE AND deliver all Know-How relating to such
          enhancements, modifications and improvements to the Licensee, and such
          Know-How shall be included in the license granted by the Licensors to
          the Licensee pursuant to Paragraph 2.A above.

          d. Paragraph 4.A(2) of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               (2) Licensors agree to cooperate, and agree to cause their
          Affiliates to cooperate, with Licensee in the preparation, filing,
          prosecution and maintenance of the Licensed Patents by disclosing such
          information as may be necessary for the same and by promptly executing
          such documents as Licensee may reasonably request in connection
          therewith. Licensors and their Affiliates shall bear their own costs
          in connection with their cooperation with Licensee under this
          Paragraph. IN CONNECTION WITH THE FOREGOING, ON OR PRIOR TO THE DATE
          HEREOF, THE LICENSORS AND JSC SHALL HAVE DELIVERED TO LICENSEE COPIES
          OF ALL TANGIBLE INFORMATION AND DOCUMENTATION IN THEIR POSSESSION
          RELATING TO THE LICENSED TECHNOLOGY.

          e. Paragraph 5.B of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               5.B JSC. JSC represents and warrants that: (i) the Licensed
          TECHNOLOGY IS free and clear of any lien, encumbrance, security
          interest or restriction on license; (ii) when executed and delivered,
          this Agreement will become valid and binding on JSC and enforceable
          against JSC in accordance with its terms; (iii) he has not previously
          granted, and will not grant during the term of this Agreement, any
          right, license or interest in and to the Licensed TECHNOLOGY, or any
          portion thereof, inconsistent with the license granted to Licensee
          herein; (iv) the Licensed TECHNOLOGY IS free and clear of any lien,
          encumbrance, security interest or restriction on license; (v) there
          are no threatened or pending actions, suits, investigations, claims or
          proceedings in any way

<PAGE>

          relating to the Licensed TECHNOLOGY; and (vi) as of the date of this
          Agreement, he has assigned to NV and/or BV all of the patents and
          patent applications owned by him that relate in any way to intraocular
          lenses including all divisions, continuations, continuations-in-part,
          foreign counterparts and any reissues renewals, substitutions or
          extensions of or to any such patents or patent applications.

          f. Paragraph 5.C of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               5.C NV. NV represents and warrants that: (i) it is a corporation
          duly organized validly existing and in good standing under the laws of
          the Netherlands Antilles; (ii) when executed and delivered, this
          Agreement will become valid and binding on NV and enforceable against
          NV in accordance with its terms; (iii) the execution, delivery and
          performance of this Agreement have been duly authorized by all
          necessary corporate action on the part of NV; (iv) it had the right to
          grant the rights and licenses relating to the Licensed TECHNOLOGY
          previously granted to BV; (v) the Licensed TECHNOLOGY IS free and
          clear of any lien, encumbrance, security interest or restriction on
          license; (vi) it has not previously granted, and will not grant during
          the term of this Agreement, any right, license or interest in and to
          the Licensed TECHNOLOGY, or any portion thereof, inconsistent with the
          license granted to Licensee herein; and (vii) there are no threatened
          or pending actions, suits, investigations, claims or proceedings in
          any way relating to the Licensed TECHNOLOGY.

          g. Paragraph 5.D of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               5.D BV. BV represents and warrants that: (i) it is a corporation
          duly organized validly existing and in good standing under the laws of
          the Netherlands; (ii) when executed and delivered, this Agreement will
          become valid and binding on BV and enforceable against BV in
          accordance with its terms; (iii) the execution, delivery and
          performance of this Agreement have been duly authorized by all
          necessary corporate action on the part of BV; (iv) it had the right to
          grant the rights and licenses relating to the Licensed Patents
          previously granted to Licensee; (v) the Licensed TECHNOLOGY IS free
          and clear of any lien, encumbrance, security interest or restriction
          on license; (vi) it has not previously granted, and will not grant
          during the term of this Agreement, any right, license or interest in
          and to the Licensed TECHNOLOGY, or any portion thereof, inconsistent
          with the license granted to Licensee herein; and (vii) there are no
          threatened or pending actions, suits, investigations, claims or
          proceedings in any way relating to the Licensed TECHNOLOGY.

          h. Paragraph 5.F(3) of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

<PAGE>

               5.F(3) Procedure. In the event that any Indemnitee intends to
          claim indemnification under this Paragraph 5.F. it shall promptly
          notify the other party in writing of such alleged Liability. EXCEPT AS
          SET FORTH IN PARAGRAPH 7 BELOW, the indemnifying party shall have the
          right to control the defense thereof. The affected Indemnitees shall
          cooperate fully with the indemnifying party and its legal
          representatives in the investigation and conduct of any Liability
          covered by this Paragraph 5.F. The Indemnitee shall not, except at its
          own cost, voluntarily make any payment or incur any expense with
          respect to any claim, suit or Liability, or make any admission of
          liability or attempt to settle any claim without the prior written
          consent of the indemnifying party, which such party shall not be
          required to give.

          i. Paragraph 6.A of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               6.A Confidentiality, Publications and Data Access. All
          information submitted by JSC AND/OR LICENSORS to LICENSEES concerning
          the invention(s) claimed in the Licensed Patents, Licensed Technology
          and Licensed Products shall be considered as confidential
          ("Confidential Information"). During the term of this Agreement and
          for a period of ten (10) years thereafter, NEITHER JSC NOR EITHER OF
          THE LICENSORS shall disclose to any third party any Confidential
          Information without the specific written consent of Licensee. The
          foregoing shall not apply where such Confidential Information a) was
          or becomes public through no fault of the receiving party or b) is
          required by law to be disclosed to a court or governmental agency.
          WITHOUT LIMITING THE FOREGOING, LICENSEE HEREBY AGREES TO PROTECT THE
          CONFIDENTIALITY OF THE CONFIDENTIAL INFORMATION TO THE SAME EXTENT IT
          PROTECTS ITS OWN PROPRIETARY INFORMATION.

          j. Paragraph 6.B of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               6.B Permitted Use and Disclosures. Notwithstanding Paragraph 6.A.
          above, JSC AND THE LICENSORS may use or disclose CONFIDENTIAL
          Information SOLELY to the extent such use or disclosure is reasonably
          necessary in filing or prosecuting patent applications, prosecuting or
          defending litigation, complying with applicable governmental
          regulations or otherwise submitting information to tax or other
          governmental authorities or otherwise exercising its rights hereunder,
          provided that if JSC OR EITHER OF THE LICENSORS is required to make
          any such disclosure of Confidential Information, it will give
          reasonable advance notice to LICENSEE of such disclosure and, save to
          the extent inappropriate in the case of patent applications, will use
          its best efforts to secure confidential treatment of such CONFIDENTIAL
          Information prior to its disclosure (whether through protective orders
          or otherwise).

<PAGE>

          k. Paragraph 6.C of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               6.C Confidential Terms. Except as expressly provided herein, each
          party agrees not to disclose any terms of this Agreement to any third
          party without the consent of the other parties; provided, disclosures
          may be made as required by securities or other applicable laws, or to
          actual or prospective investors, ACQUIRORS or corporate partners, or
          to a party's accountants, attorneys and other professional advisors.

          l. Paragraph 6.D of the License Agreement shall be deleted in its
entirety and shall be replaced with the words "Intentionally Omitted."

          m. Paragraph 7.A of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               7.A Notice. Each party shall give the others written notice if
          one of them becomes aware of any infringement by a third party of any
          Licensed Patent. Upon notice of any such infringement, the parties
          shall MAKE A GOOD FAITH EFFORT TO promptly consult with one another
          with a view toward reaching agreement on a course of action to be
          pursued. NOTWITHSTANDING THE FOREGOING, LICENSEE AND ANY SUBLICENSEE
          SHALL HAVE THE RIGHT TO INSTITUTE AND PROSECUTE AN INFRINGEMENT
          ACTION.

          n. Under Paragraph 10.E of the License Agreement, the following shall
be added under the notice provision for Licensee:

             With a copy to: C & C Vision, Inc.
                             6 Journey, Suite 270
                             Aliso Viejo, California 92656
                             Attn: President

          o. Paragraph 10.N of the License Agreement shall be restated in its
entirety to read as follows (with the changes indicated in bold):

               10.N Further Assurances. At any time or from time to time on and
          after the date of this Agreement, JSC AND Licensors and each of them
          shall at the request of Licensee (i) deliver to Licensee such records,
          data or other documents consistent with the provisions of this
          Agreement, (ii) execute, and deliver or cause to be delivered, all
          such consents, documents or further instruments of transfer or
          license, and (iii) take or cause to be taken all such actions, as
          Licensee may reasonably deem necessary or desirable in order for
          Licensee to obtain the full benefits of this Agreement and the
          transactions contemplated hereby.

<PAGE>

          p. Exhibit B to the License Agreement shall be amended as follows:

               The following patents shall be added under the column labeled
          "Issued Patents":

          q. Except as expressly amended hereby, the License Agreement shall
remain in full force and effect.

     2. Counterparts. This Amendment may be executed in two counterparts, each
of which shall be deemed an original and which together shall constitute one
instrument.

<PAGE>

     IN WITNESS WHEREOF, JSC, Licensors and Licensee have executed this
Amendment by duly authorized officers.

EPPINGTON CORPORATION, N.V.

By: /s/ Illegible
    ---------------------------------
Print Name: Illegible
Title: Managing Director

MEDEVEC LICENSING, B.V.

By: /s/ Illegible
    ---------------------------------
Print Name: HOLLAND INTERTRUST
            CORPORATION B.V.
Title: Managing Director

MEDEVEC SUPPLIES LIMITED

By: /s/ Illegible
    ---------------------------------
Print Name: Illegible
Title: DIRECTOR

J. STUART CUMMING

/s/ J. Stuart Cumming
-------------------------------------
J. Stuart Cumming
<PAGE>

2. Licensors hereby acknowledge that, as of the date hereof, Licensee is not, to
the Licensors' knowledge, in breach of the C&C International License Agreement.

3. Licensee and JSC hereby consent to the assignment by the Licensors of all of
Licensors' right, title and interest in the C&C International License Agreement
to the Nice Trust subject to the terms and conditions of this C&C International
Consent. Upon: (i) receipt by Licensee and JSC of a fully executed C&C
International Consent; and (ii) Licensee and JSC's receipt of written notice of
the consummation of the BV/NV Assignment, Licensee shall recognize the Nice
Trust as having all of the rights and interests in and obligations under the C&C
International License Agreement heretofore attributed to the Licensors.

4. The Nice Trust acknowledges that it has reviewed the C&C International
License Agreement and fully understands the obligations set forth therein on its
part to be performed thereunder.

5. The Nice Trust hereby agrees to be responsible for and assume all duties,
liabilities and obligations of the Licensors under the C&C International License
Agreement prior to, on, or following the date of the Assignment; provided
however that the Licensors and the Nice Trust shall be jointly and severally
liable for all liabilities arising on or prior to the date of the BV/NV
Assignment. The Nice Trust shall be obligated to the terms of the C&C
International License Agreement and any agreement contained therein as if it
were an original party thereto.

6. Section 1(K) of the C&C International License Agreement is hereby amended and
restated in its entirety to read as follows:

   ""Territory" means worldwide excluding the United States."

7. Notwithstanding anything to the contrary in the BV/NV Assignment or this C&C
International Consent, each of the Licensors agrees to continue to cooperate,
and to cause their Affiliates (as defined in the C&C International License
Agreement) to cooperate, with Licensee in the preparation, filing, prosecution
and maintenance of the Licensed Patents (as defined in the C&C International
License Agreement) by disclosing such information as may be necessary for the
same and by promptly executing such documents as Licensee may reasonably request
in connection therewith. Each of the Licensors and their Affiliates shall bear
their own costs in connection with their cooperation with Licensee under this
paragraph.

8. Each of the Licensors and the Nice Trust hereby agree to jointly and
severally indemnify, defend and hold harmless Licensee and Licensee's directors,
officers, employees, agents, and Affiliates (each a "LICENSEE INDEMNITEE") from
and against any and all claims, liabilities, damages, losses, costs or expenses
(including attorneys' and professional fees and other expenses of litigation
and/or arbitration) (a "LIABILITY") resulting from any claim, suit or proceeding
brought by a third party against a Licensee Indemnitee, arising out of or in
connection with the BV/NV Assignment and the transactions contemplated thereby
and hereby or out of any breach of this C&C
<PAGE>
International Consent by any of the Licensors or the Nice Trust. In the event
that any Licensee Indemnitee intends to claim indemnification under this
Paragraph 12, it shall promptly notify the other party in writing of such
alleged Liability. The indemnifying party shall have the right to control the
defense thereof. The affected Licensee Indemnitees shall cooperate fully with
the indemnifying party and its legal representatives in the investigation and
conduct of any Liability covered by this Paragraph 12. The Licensee Indemnitee
shall not, except at its own cost, voluntarily make any payment or incur any
expense with respect to any claim, suit or Liability, or make any admission of
liability or attempt to settle any claim without the prior written consent of
the indemnifying party, which consent shall not be unreasonably withheld.

9. Article 10(F) of the C&C International License Agreement shall be amended and
restated in its entirety to read as follows:

      "10(F). Assignment. This Agreement shall be binding on the parties hereto
      and upon their respective successors and assigns. Licensee may transfer or
      assign this Agreement or any of Licensee=s rights hereunder without the
      written consent of Licensors or JSC. Neither JSC nor the Licensors may
      assign or delegate to a successor any of its rights and obligations
      hereunder without the express written consent of Licensee."

10. This C&C International Consent shall be binding on the parties hereto and
upon their respective successors and assigns. Licensee may transfer or assign
this C&C International Consent or any of Licensee=s rights hereunder without the
written consent of Licensors or JSC. Neither JSC, the Licensors, nor the Nice
Trust may assign or delegate to a successor any of its rights and obligations
hereunder without the express written consent of Licensee.

11. All of the covenants and agreements contained in this C&C International
Consent shall be binding upon and shall inure to the benefit of the parties
hereto and their respective representatives, successors and assigns.

12. This C&C International Consent may be executed in counterparts, all of
which, when taken together, shall constitute one and the same C&C International
Consent.

13. This C&C International Consent, and any dispute, including without
limitation any arbitration, arising from the performance or breach hereof shall
be governed by and construed and enforced in accordance with the laws of the
state of California, without reference to conflicts of laws principles. The
exclusive venue of any dispute arising out of or in connection with the
performance or breach of this Agreement shall be the California state courts or
U.S. district court located in San Francisco, California, and the parties hereby
consent to the personal jurisdiction of such courts.

14. If any provision of this C&C International Consent is held to be illegal or
unenforceable, that provision will be limited or eliminated to the minimum
extent necessary so that this C&C International Consent will otherwise remain in
full force and effect and enforceable so as to give effect to the intent of the
parties hereunder.

<PAGE>

15. This C&C International Consent shall become effective pursuant to the terms
set forth in Section 3 hereof and only if and when the BV/NV Assignment is
consummated, in which case this C&C International Consent shall become effective
upon the closing date of the BV/NV Assignment; provided, however, that if the
closing of the BV/NV Assignment has not occurred as of the date hereof, then
Licensee shall not give its consent to any assignment of Licensors' rights and
obligations under this C&C International Consent and this C&C International
Consent shall be null and void.

                [remainder of this page intentionally left blank]
<PAGE>
     IN WITNESS WHEREOF, the parties hereto have each duly executed this
Consent to Assignment and Second Amendment of Medevec License Agreement
effective as of the Effective Date. Each party warrants and represents that its
respective signatories whose signatures appear below have been and are, on the
date of signature, authorized to execute this C&C International Consent.

                                J. STUART CUMMING

                                /s/ J. Stuart Cumming
                                --------------------------------------------

                                EPPINGTON CORPORATION NV

                                By:  Fortis Intertrust [ILLEGIBLE] N.V.
                                     ----------------------------------
                                Name: G.E. Elias V.M.G. Haseth-Portillo

                                Title: Managing Director Proxyholder "A"

                                MEDEVEC LICENSING BV

                                By: /s/ [ILLEGIBLE]
                                    -----------------------------------------
                                Name: MeesPierson Intertrust (Amsterdam) B.V.

                                Title: Managing Director

                                C&C VISION INTERNATIONAL LIMITED

                                By: /s/ Steven J. Naber
                                    -----------------------------------------
                                Name: Steven J. Naber

                                Title: Chairman

                                JAMES ELLWOOD AND JULIA DOROTHY KNEEN
                                AS TRUSTEE OF THE NICE TRUST

                                By: /s/ James Ellwood, /s/ Julia D Kneen
                                    -----------------------------------------
                                Name: James  Ellwood    Julia D Kneen

                                Title: Trustee          Trustee
<PAGE>

                THIRD AMENDMENT TO THE C&C INTERNATIONAL LICENSE
                                    AGREEMENT

This Third Amendment to the C&C International License Agreement (this "AMENDMENT
#3"), effective as of January 1, 2007 (the "EFFECTIVE DATE"), is made by and
between C&C Vision International Limited, an Irish corporation and formerly
Medevec Supplies, Ltd. ("LICENSEE") and James Ellwood and Julia Dorothy Kneen as
Trustees of the Nice Trust (the "NICE TRUST"). Licensee and the Nice Trust may
be referred to herein by name or as a "PARTY," or collectively as the "PARTIES."

                                   BACKGROUND

WHEREAS, Licensee entered into that certain license agreement with J. Stuart
Cumming, Eppington Corporation, N.V. and Medevec Licensing B.V. dated October
12, 1998, as amended May 31, 2000 and December 31, 2006 under which Eppington
Corporation, N.V. and Medevec Licensing B.V. granted certain rights and licenses
to Licensee and each party undertook certain obligations to the other (such
license agreement, the "C&C INTERNATIONAL LICENSE AGREEMENT").

WHEREAS, the Nice Trust has been assigned all rights and obligations as
"Licensor" under that certain BV/NV Assignment and Assumption Agreement by and
among J. Stuart Cumming, Eppington Corp. N.V., Medevec Licensing B.V. and James
Ellwood and Julia Dorothy Kneen as Trustees of the Nice Trust dated December 31,
2006 (the "BV/NV ASSIGNMENT AND ASSUMPTION AGREEMENT").

WHEREAS, the Nice Trust wishes to amend the C&C International License Agreement
to provide for a reduction in the royalty payable by Licensee to the Nice Trust
in order to provide for a royalty to be paid by Licensee to J. Andy Corley,
currently a Director of Licensee, whom the Nice Trust acknowledges has increased
sales of Licensed Products and the growth of Licensee to the economic benefit of
the Nice Trust.

NOW, THEREFORE, in consideration of the covenants and promises set forth herein
and for other good and valuable consideration, the receipt and sufficiency of
which are hereby expressly acknowledged by the Parties, each of the undersigned
covenants and agrees as follows:

      1.    A new Section 3.D. is hereby added to the C&C International License
            Agreement, and reads as follows:

            "3.D. Notwithstanding anything to the contrary in this Agreement
            (including, without limitation, the terms of Paragraph 3.A.(1) or
            7.B(3) hereof), after all applicable reductions and off-sets
            (including, without limitation, those set forth in Paragraphs
            3.A.(3), (4), (5), (6) and (7) and 7.C.(3) below) have been applied
            against the amounts owed by Licensee to BV under this Agreement, the
            amounts owed by Licensee to BV hereunder (net of such reductions and
            off-sets) shall be reduced by a further twenty percent (20%), such
            that the actual amounts payable by Licensee to BV under this
            Agreement shall be eighty percent (80%) of what
<PAGE>

            their value would have been calculated to be prior to reduction
            pursuant to this Section 3.D."

      2.    Licensee shall be entitled to deduct and withhold from any payment
            made under the C&C International License Agreement any amounts
            required to be deducted and withheld under the Internal Revenue Code
            (including, without limitation, income and payroll taxes), or any
            provision of state, local or foreign tax law, with respect to the
            making of such payment. To the extent that amounts are so withheld,
            such withheld amounts shall be treated for all purposes of the C&C
            International License Agreement as having been paid.

      3.    Each Party represents and warrants that: (i) it has full power and
            authority to enter into and perform this Amendment #3; (ii) its
            entering into of this Amendment #3 will not violate any right of or
            breach any obligation to any third party under any agreement or
            arrangement between such Party and such third party; and (iii) its
            execution, delivery and performance of this Agreement has been duly
            authorized by such Party. The Nice Trust further represents and
            warrants that it is a Discretionary Trust established under the laws
            of the Isle of Man, and Licensee further represents and warrants
            that it is a corporation established under the laws of Ireland.

      4.    All of the covenants and agreements contained herein shall be
            binding upon and shall inure to the benefit of the Parties hereto
            and their respective representatives, successors and assigns.

      5.    This Amendment #3 and any dispute, including without limitation any
            arbitration, arising from the performance or breach hereof shall be
            governed by and construed and enforced in accordance with the laws
            of the State of California, without reference to conflicts of laws
            principles, and the 1980 U.N. Convention on Contracts for the
            International Sale of Goods shall not apply to this Amendment #3,
            the C&C International License Agreement or the rights or obligations
            of the Parties therein. The exclusive venue of any dispute arising
            out of or in connection with the performance or breach of this
            Amendment #3 shall be the California state courts or U.S. district
            court located in San Francisco, California, and the Parties hereby
            consent to the personal jurisdiction of such courts.

      6.    Capitalized terms undefined herein shall have the meanings ascribed
            to them in the C&C International License Agreement.

      7.    This Amendment #3 may be executed in counterparts, all of which,
            when taken together, shall constitute one and the same Amendment #3.

                [remainder of this page intentionally left blank]
<PAGE>
      IN WITNESS WHEREOF, the Parties hereto have each duly executed this
Amendment #3 effective as of the Effective Date. Each Party warrants and
represents that its respective signatories whose signatures appear below have
been and are, on the date of signature, authorized to execute this amendment #3.

                                       C&C VISION INTERNATIONAL LIMITED

                                       By:   /s/ Steven J. Naber
                                             ---------------------------
                                       Name: Chairman
                                             ---------------------------
                                       Title:[ELLIGIBLE]
                                             ---------------------------

                                       JAMES ELLWOOD AND JULIA
                                       DOROTHY KNEEN AS TRUSTEES OF
                                       THE NICE TRUST

                                       By:   /s/ J. Ellwood, Julia Dorothy Kneen
                                             ---------------------------
                                       Name: J. Ellwood, Julia Dorothy Kneen
                                             ---------------------------
                                       Title: Trustee, Trustee,
                                             ---------------------------<PAGE>
                                                                   EXHIBIT 10.14

                           EXCLUSIVE LICENSE AGREEMENT

This Agreement ("Agreement") effective as of March 29, 2006 (the "Effective
Date") between eyeonics, inc having its principle place of business at 26970
Aliso Viejo Parkway, Suite #100, Aliso Viejo, CA 92656 ("eyeonics") and Steven
Dell, M.D., an individual, ("Dr. Dell").

WHEREAS, Dr. Dell owns, or has an ownership interest in, the drawings of the
SD2, SD3 and SD4 intraocular lens; certain improvements, modifications and
derivatives thereof; and related subject matter (the "Inventions").

WHEREAS, Dr. Dell desires to grant to eyeonics an exclusive license under all of
his right, title and interest in the Inventions and eyeonics desires to receive
such license, all as described in more detail below.

NOW, THEREFORE, for good and valuable consideration the receipt and adequacy of
which is acknowledged, the parties hereto agree as follows:

                                    ARTICLE 1
                                  DEFINITIONS

"Affiliate" shall mean any entity which controls, is controlled by or is under
common control with eyeonics. For purposes of this definition, an entity shall
be regarded as in control of another entity for purposes of this definition if
it owns or controls fifty percent (50%) or more of the shares of the subject
entity entitled to vote in the election of directors (or, in the case of an
entity that is not a corporation, for the election of the corresponding managing
authority).

"Field" shall mean any and all applications.

"Licensed Patents" shall mean any and all of Dr. Dell's right, title and
interest in and to:

     i.   all worldwide  patent and patent  applications  claiming or disclosing
          subject  matter  claimed  or  disclosed  in the  patent(s)  and patent
          application(s)  listed  in  Exhibit  A  hereto  and all  improvements,
          derivatives and modifications to such subject matter (collectively the
          "Patent Rights"); and

     ii.  all  divisions,  continuations,   continuations-in-part,   patents  of
          addition,  and  substitutions of the Patent Rights,  together with all
          registrations, reissues, reexaminations or extensions of any kind with
          respect to any of the foregoing patents.

"Licensed Product" shall mean a Product the manufacture, sale or use of which
would, but for the license granted herein, infringe a Valid Claim within the
Licensed Patents in the country for which such Product is sold.

"Net Sales" shall mean the amounts actually received by eyeonics or its
Sublicensees for the sale or other disposition to an unaffiliated third party
for Licensed Products, as applicable, less the following reasonable and
customary deductions to the extent applicable to such invoiced amounts: (i) all
trade, cash and quantity credits, discounts or refunds; (ii) amounts for claims,
allowance or credits for returns, retroactive price reductions, chargebacks; and
(iii) packaging, handling fees and prepaid freight, sales, taxes, duties and
other governmental charges (including value-added tax), but excluding what is
commonly known as income taxes. For the removal of doubt, Net Sales shall not
include sales by eyeonics to its Affiliates for resale; provided that if
eyeonics sells a Licensed Product to an Affiliate for resale, Net Sales shall
include the amounts invoiced by such Affiliate to third parties on the resale of
such Licensed Product. In addition, Net Sales shall not include shipments of
Licensed Products made by eyeonics, its Sublicensees or its Affiliates to third
parties at no or low cost in connection with research and development or
clinical trials.

"Product" shall mean a product, composition or material.

"Sublicensee" shall mean any non-Affiliate third party to whom eyeonics has
granted the right to manufacture and sell Licensed Products.

"Territory" shall mean worldwide.

"Valid Claim" shall mean a claim of an issued and unexpired patent or a claim of
a pending patent application within the Licensed Patents which has not been held
unpatentable, invalid or unenforceable by a court or other government agency of
competent jurisdiction and has

<PAGE>

not been admitted to be invalid or unenforceable through reissue,
re-examination, disclaimer or otherwise; provided, however, that if the holding
of such court or agency is later reversed by a court or agency with overriding
authority, the claim shall be reinstated as a Valid Claim with respect to Net
Sales made after the date of such reversal. Notwithstanding the foregoing
provisions of this paragraph, if a claim of a pending patent application has not
issued as a claim of an issued patent, within five (5) years after the date from
which such claim takes priority, such pending claim shall not be a Valid Claim
for purposes of this Agreement unless and until the patent is issued including
such claim.

                                    ARTICLE 2
                                     LICENSE

2.1 License. Dr. Dell hereby grants to eyeonics an exclusive license under any
and all of Dr. Dell's right, title and interest in and to the Licensed Patents:
(i) to make, have made, use, sell, have sold, import and have imported Licensed
Products, and (ii) to otherwise exploit the Licensed Patents; and to have any of
the foregoing performed on its behalf by a third party for all applications.

2.2 Sublicenses. eyeonics may grant and authorize sublicenses to Sublicensees
within the scope of the license granted to eyeonics pursuant to this Agreement.

2.3 Know-How. At the reasonable request and reasonable expense of eyeonics, Dr.
Dell agrees to transfer to eyeonics all know-how in his control that is
necessary or useful to enable eyeonics to practice the license granted herein
and, at the reasonable request and reasonable expense of eyeonics, to make
himself available at reasonable times to assist eyeonics in such enablement.

                                    ARTICLE 3
                                    ROYALTIES

3.1 Base Royalty. In consideration of the rights and licenses granted by Dr.
Dell to eyeonics herein, eyeonics agrees to pay to Dr. Dell a running royalty of
*** percent (***%)1 of Net Sales of Licensed Products.

3.2 Royalty Term. The running royalties under Section 3.1 shall be payable on a
Licensed Product-by-Licensed Product and country-by-country basis on the Net
Sales of such Licensed Product by eyeonics or its Affiliates and only for the
period until the later of: (i) the abandonment of the last patent application
within the Licensed Patents or (ii) the expiration of the last to expire of the
patents within the Licensed Patents, in each case that contains a claim that
would be infringed by the manufacture, sale or use of such Licensed Product in
such country (such period, the "Royalty Term" for such Licensed Product).

3.3 Multiple Royalties. If eyeonics or its Affiliate is required to pay a third
party amounts with respect to a Licensed Product under agreements for patent
rights or other technologies which eyeonics, in its reasonable judgment,
determines are necessary or desirable to license or acquire with respect to such
Licensed Product, eyeonics may deduct such amount owing to such third parties
(prior to any reductions) from the royalty owing to Dr. Dell for the sale of
such Licensed Product pursuant to Section 3.1 above. Notwithstanding the
foregoing provisions of this Section 3.3, in no event shall the royalties due to
Dr. Dell pursuant to Section 3.1 above be so reduced to less than *** percent
(***%)2 of the amount that would otherwise be due Dr. Dell thereunder.

3.4 Combination Products. In the event that a Licensed Product is sold in
combination with another product, component or service for which no royalty
would be due hereunder if sold separately, Net Sales from such combination sales
for purposes of calculating the amounts due under this Article 3 shall be
calculated by multiplying the Net Sales of the combination product by the
fraction A/B, where A is the average gross selling price during the previous
calendar quarter of the Licensed Product sold separately and B is the gross
selling price during the previous calendar quarter of the combined product(s),
component(s) and/or service(s). In the event that a substantial number of such
separate sales were not made during the previous calendar quarter then the Net
Sales shall be as reasonably allocated by eyeonics between such Licensed Product
and such other product(s), component(s) or service(s) based upon their relative
importance and proprietary protection.

3.5 Records. During the Royalty Term and for a period of three (3) years
thereafter, eyeonics shall keep complete and accurate records of its and its
Affiliates' Net Sales in sufficient detail to enable the amounts payable under
this Article 3 to be determined. Upon Dr. Dell's written request, but not more
frequently than once per calendar year, eyeonics shall permit representatives or
agents of Dr. Dell, at Dr. Dell's expense, to examine such records during
eyeonics's regular business hours for the purpose of and to the extent necessary
to verify any report required under this Agreement with respect to Net Sales
received not more than three (3) years prior to the date of Dr.

----------

1 *** Indicates that confidential treatment has been sought for this
information.

<PAGE>

Dell's request. In the event that the amounts due to Dr. Dell are determined to
have been underpaid, eyeonics shall pay to Dr. Dell any amount due and unpaid,
together with interest on such amount at the U.S. prime rate quoted in the
"Money Rates" column of The Wall Street Journal (U.S., Eastern Edition) on the
first business day after such unpaid amount is discovered, or at the maximum
rate permitted by law, whichever is lower. eyeonics records examined by Dr. Dell
hereunder shall be considered Confidential Information (as defined in Article 5
below).

3.6 Reports. Beginning with the first accrual of Net Sales on which a royalty is
due hereunder and until the end of the Royalty Term, eyeonics shall provide to
Dr. Dell a semi-annual royalty report as follows: Within sixty (60) days after
the end of each semi-annual period, eyeonics shall deliver to Dr. Dell a true
and accurate report, giving such particulars of the business conducted by
eyeonics and its Affiliates, if any, during such semi-annual period as are
pertinent to account for royalties due under this Article 3. Such report shall
include at least (i) the total of Net Sales during such semi-annual period; (ii)
the calculation of royalties; and (iii) the total royalties so calculated and
due Dr. Dell. Simultaneously with the delivery of each such report, eyeonics
shall pay to Dr. Dell the total royalties, if any, due to Dr. Dell for the
period of such report. If no royalties are due, eyeonics shall so report. Dr.
Dell shall not provide to third parties any information contained in reports
provided to Dr. Dell under this Section 3.6, or learned by Dr. Dell under
Section 3.5 above. The reports provided to Dr. Dell by eyeonics hereunder and
all information contained therein shall be considered Confidential Information.

3.7 Payments. All amounts payable hereunder by eyeonics shall be payable in
United States Dollars to Dr. Dell. If any currency conversion shall be required
in connection with the payment of royalties hereunder, such conversion shall be
made by using the exchange rates used by eyeonics in calculating eyeonics's own
revenues for financial reporting purposes. Any payments due under this Agreement
which are not paid by the date such payments are due under this Agreement shall
bear interest to the extent permitted by applicable law at the rate set forth in
Section 3.6 above on the first business day after such payment is due,
calculated on the number of days such payment is delinquent.

3.8 Taxes. Any withholding or other tax that is required by law to be withheld
on behalf of eyeonics with respect to payments owed by eyeonics pursuant to this
Agreement shall be deducted by eyeonics from such payment prior to remittance.
eyeonics shall promptly furnish Dr. Dell evidence of any such taxes withheld.

                                    ARTICLE 4
                                 PATENT MATTERS

4.1 Prosecution and Maintenance.

     i. eyeonics shall have the right, at its option, to control the filing for,
prosecution and maintenance of the Licensed Patents. For purposes of this
Article 4, "prosecution and maintenance" of patents and patent applications
shall be deemed to include, without limitation, the conduct of interferences or
oppositions, and/or requests for re-examinations, reissues or extensions of
patent terms. In the event that eyeonics elects not to file, prosecute or
maintain any patent application or patent within the Licensed Patents or pay any
fee related thereto, in any country eyeonics shall promptly notify Dr. Dell of
such election, but in no case later than sixty (60) days prior to any required
action relating to the filing, prosecution or maintenance of such patent or
patent application. From and after the effective date of such notice, such
patent application or patent shall cease to be within the Licensed Patents for
all purposes of this Agreement, and all rights and obligations of eyeonics with
respect thereto shall terminate and revert to Dr. Dell.

     ii. Subject to eyeonics' election rights in the third sentence of part (i)
above of in this Section 4.1, eyeonics agrees to use its commercially reasonable
efforts to obtain patent protection for the SD4 intraocular lens design in the
United States, Europe and Asia in its prosecution and maintenance of the
Licensed Patents.

4.2 Enforcement. If either party determines that a third party is making, using
or selling a product that may infringe the Licensed Patents, that party shall
notify the other party in writing.

     i. eyeonics shall have the first right (itself or through others), at its
sole option, to bring suit to enforce the Licensed Patents, and/or to defend any
declaratory judgment action with respect thereto; provided, however, that
eyeonics shall keep Dr. Dell reasonably informed as to the defense and/or
settlement of such action. Dr. Dell shall have the right to participate in any
such action with counsel of its own choice at its own expense. All recoveries
received by eyeonics from an action to enforce the Licensed Patents shall be
first applied to reimburse eyeonics' and then Dr. Dell's unreimbursed expenses,
including without limitation, reasonable attorney's fees and court costs. Any
remainder shall, to the extent the same pertains to an infringement of the
Licensed Patents, be treated as Net Sales of Licensed Products.

     ii. In the event eyeonics elects not to initiate an action to enforce the
Licensed Patents against a commercially significant infringement by a third
party, within six (6) months of a request by Dr. Dell to do so, (or within such
shorter period which may be required to preserve the legal rights of Dr. Dell
under the laws of the relevant government), Dr. Dell may initiate such action at
its expense with

<PAGE>

eyeonics' prior written consent, which consent shall not be unreasonably
withheld. eyeonics shall have the right to participate in any such action with
counsel of its own choice at its own expense. All recoveries received by Dr.
Dell from an action to enforce the Licensed Patents shall be first applied to
reimburse Dr. Dell's and then eyeonics' unreimbursed expenses, including without
limitation, reasonable attorney's fees and court costs. Any remainder shall, to
the extent the same pertains to an infringement of the Licensed Patents, be
divided *** percent (***%)2 to Dr. Dell and *** percent (***%) to eyeonics.

     iii. eyeonics (itself or through its designees) agrees to use commercially
reasonable efforts to enforce the Licensed Patents against commercially
significant infringements and declaratory judgment actions, in each case without
cost to Dr. Dell.

4.3 Cooperation. In any suit, action or other proceeding in connection with
enforcement and/or defense of the Licensed Patents, Dr. Dell shall cooperate
fully, including without limitation by joining as a party plaintiff and
executing such documents as eyeonics may reasonably request. Upon the request of
and, at the expense of eyeonics, Dr. Dell shall make available at reasonable
times and under appropriate conditions all relevant personnel, records, papers,
information, samples, specimens and other similar materials in each of its
possession.

4.4 No Implied Obligations. Except as expressly provided in this Article 4,
neither party has any obligation to bring or prosecute actions or suits against
any third party for patent.

                                    ARTICLE 5
                                 CONFIDENTIALITY

Dr. Dell agrees that, during the term of this Agreement and for a period of
three (3) years thereafter, Dr. Dell shall not disclose, without the prior
written consent of eyeonics, any eyeonics Confidential Information. As used
herein, "Confidential Information" means all information and/or trade secrets
relating to eyeonics' management, business, operations, technology, products or
business plans, which Dr. Dell knows or has reason to know is regarded as
confidential by eyeonics and includes without limitation any information
relating to the Inventions (including information generated by Dr. Dell whether
before or after the Effective Date). Confidential Information shall not include
information that Dr. Dell can demonstrate (i) has become part of the public
domain except by breach of this Agreement; (ii) Dr. Dell knew prior to the
disclosure of such Confidential Information by eyeonics to Dr. Dell, in the case
of Confidential Information disclosed by eyeonics to Dr. Dell; or (iii) Dr. Dell
learned from a third party source having no duty of confidentiality to eyeonics.
Dr. Dell may lecture upon, disseminate and publish under Dr. Dell's own name
scientific papers arising from work done relating to the Inventions, but only
upon the prior written approval of eyeonics, with such approval not to be
unreasonably withheld. For clarity, eyeonics' approval of a disclosure by Dr.
Dell pursuant to the foregoing sentence will not be deemed to be unreasonably
withheld if such disclosure would harm eyeonics' ability to commercialize the
Inventions or obtain patent protection thereof.

                                    ARTICLE 6
                         REPRESENTATIONS AND WARRANTIES

6.1 Warranties. Dr. Dell represents and warrants that: (i) his ownership
interest in and to the Licensed Patents free and clear of any liens or
encumbrances; (ii) he has not previously granted and will not grant any rights
in the Licensed Patents to any third party; (iii) except for the Licensed
Patents, as of the Effective Date, he does not own or control any patent or
patent application (including any invention disclosure or draft patent
application for which a patent application is intended to be filed) the claims
of which would dominate any practice of the Inventions; (iv) as of the Effective
Date, there are no actions, suits or proceedings pending or threatened in
writing against him at law or in equity by or before any third party, federal,
state or other governmental department, agency or instrumentality, domestic or
foreign, which may in any way adversely affect eyeonics' rights hereunder or
otherwise call into question his rights to transfer to eyeonics the rights
contemplated hereunder; (v) from January 1, 2004 through the Effective Date,
there are no other inventions, whether patentable or not, other than the
Inventions licensed herein, conceived, made or reduced to practice by Dr. Dell
related to eyeonic's technology; and (vi) the Inventions have not been developed
under any funding agreement with the Government of the United States.

6.2 Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY
WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT
TO THE SUBJECT MATTER HEREOF, AND BOTH PARTIES

2 *** Indicates that confidential treatment has been sought for this
information.

<PAGE>

SPECIFICALLY DISCLAIM ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSES AND NONINFRINGEMENT OF THIRD
PARTY INTELLECTUAL PROPERTY RIGHTS.

                                    ARTICLE 7
                                 INDEMNIFICATION

eyeonics shall defend and indemnify Dr. Dell from and against any and all
claims, suits or proceedings brought by third parties (including reasonable
attorneys' fees) (any of the foregoing, a "Claim") against Dr. Dell, as a direct
result of eyeonics' exercise of its rights under the Licensed Patents or gross
negligence or willful misconduct; provided, however, that eyeonics' obligations
pursuant to this Article 7 shall not apply to the extent that such Claims result
from (i) the negligence, bad faith, willful misconduct or omission of Dr. Dell;
or (ii) breach of any of the terms or conditions of this Agreement, including
the representations and warranties made by Dr. Dell in Section 6.1. Dr. Dell
shall defend and indemnify eyeonics from and against any and all Claims against
eyeonics, as a direct result from part (i) or (ii) above; provided, however,
that Dr. Dell's obligations pursuant to this Article 7 shall not apply to the
extent that such Claims result from the gross negligence or willful misconduct
of eyeonics. The obligations of a party from which indemnification is sought
under this Article 7 (such party, the "Indemnifying Party") are contingent upon
the other party (such other party, the "Indemnitee"): (a) promptly notifying the
Indemnifying Party in writing of any such Claim with respect to which it intends
to claim such indemnification; (b) giving the Indemnifying Party sole control of
the defense and/or settlement thereof (provided that the Indemnifying Party
shall not have the right to admit the fault of the Indemnitee without the prior
written consent of the Indemnitee, with such consent not to be unreasonably
withheld); and (c) providing the Indemnifying Party, at the Indemnifying Party's
expense, with reasonable assistance and full information with respect to such
Claim. The Indemnifying Party shall have no obligations for any Claim if the
Indemnitee makes any admission, settlement or other communication regarding such
Claim without the prior written consent of the Indemnifying Party, not to be
unreasonably withheld.

                                    ARTICLE 8
                                   TERMINATION

8.1 Term. Unless terminated earlier pursuant to this Article 8, the term of this
Agreement shall commence on the Effective Date and continue in full force and
effect until expiration, revocation or invalidation of the last patent or the
abandonment of the last application within the Licensed Patents.

8.2 Termination for Breach. In the event of a material breach of this Agreement,
the nonbreaching party shall be entitled to terminate this Agreement by written
notice to the breaching party, if such breach is not cured within ninety (90)
days after written notice is given by the nonbreaching party to the breaching
party specifying the breach. However, if the party alleged to be in breach of
this Agreement disputes such breach by written notice to the other party within
such ninety (90) day period, the nonbreaching party shall not have the right to
terminate this Agreement unless it has been determined by a court of competent
jurisdiction in accordance with Section 9.2 below that this Agreement was
materially breached, and the breaching party fails to comply with its
obligations hereunder within ninety (90) days after such determination.

8.3 Termination by eyeonics. Any provision herein notwithstanding, eyeonics may
terminate this Agreement, in its entirety or as to any particular patent or
patent application within the Licensed Patents, or as to any particular Licensed
Product, at any time by giving Dr. Dell at least sixty (60) days prior written
notice. From and after the effective date of a termination under this Section
8.3 with respect to a particular patent or application, such patent(s) and
patent application(s) in the particular country shall cease to be within the
Licensed Patents for all purposes of this Agreement, and all rights and
obligations of eyeonics with respect to such patent(s) and patent application(s)
shall terminate. From and after the effective date of a termination under this
Section 8.3 with respect to a particular Licensed Product, the license granted
under Section 2.1 above shall terminate with respect to such Licensed Product,
and the same shall cease to be a Licensed Product for all purposes of this
Agreement. Upon a termination of this Agreement in its entirety under this
Section 8.3, all rights and obligations of the parties shall terminate, except
as provided in Section 8.4 below.

8.4 Effect of Termination/Expiration.

     i. No Release. Termination of this Agreement for any reason shall not
release either party hereto from any liability which at the time of such
termination has already accrued to the other party.

     ii. Sublicenses. Upon termination of this Agreement for any reason, any
sublicense granted by eyeonics hereunder shall survive, provided that the
applicable Sublicensee promptly agrees in writing to pay to Dr. Dell such
amounts that would otherwise be due to Dr. Dell hereunder for such Sublicensee's
activities under such sublicense.

     iii. Articles 1, 5, 6, 7, 8 and 9 and Sections 3.5, 3.7 and 3.8 shall
survive the expiration and any termination of this Agreement. Except as
otherwise provided in this Article 8, all rights and obligations of the parties
under this Agreement shall terminate

<PAGE>

upon the expiration or termination of this Agreement.

                                    ARTICLE 9
                                  MISCELLANEOUS

9.1 Further Assurances. Dr. Dell agrees to assist eyeonics, or its designee, at
eyeonics' expense, in every proper way to secure eyeonics' rights in the
Inventions and Licensed Patents in any and all countries, including the
disclosure to eyeonics of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments which eyeonics shall deem necessary or appropriate in
order to apply for and obtain such rights and in order to assign and convey to
eyeonics, its successors, assigns, and nominees the sole and exclusive right,
title and interest in and to such Inventions and Licensed Patents. If eyeonics
is unable because of Dr. Dell's unavailability or for any other reason to secure
his signature to file, prosecute, maintain or enforce any Licensed Patent, Dr.
Dell hereby irrevocably designates and appoints eyeonics and its duly authorized
officers and agents as his agent and attorney in fact, to act for and in his
behalf and stead for any such purpose with the same legal force and effect as if
executed by Dr. Dell.

9.2 General. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, without reference to its
principles of conflicts of law. The relationship of Dr. Dell and eyeonics
established by this Agreement is that of independent contractors. Dr. Dell
agrees not to disclose any terms of this Agreement to any third party without
the consent of eyeonics, except as required by securities or other applicable
laws, to prospective and other investors and such party's accountants, attorneys
and other professional advisors. This Agreement: (i) may be assigned by eyeonics
to any entity provided that such entity agrees to be bound by the terms and
conditions contained herein (including but not limited to eyeonics' royalty
payment obligations in Article 2 above); and (ii) may be assigned by Dr. Dell
with the prior written consent of eyeonics. This Agreement shall be binding upon
the successors and assigns of the parties. All notices, requests and
communications hereunder shall be in writing and shall be personally delivered
or sent by facsimile transmission (receipt confirmed), mailed by registered or
certified mail, postage prepaid, or sent by express courier service (e.g.,
Federal Express), and shall be deemed to have been properly served to the
addressee upon receipt of such written communication, to the address of the
applicable party set forth below its signature, or such other address as may be
specified in writing to the other party. This Agreement sets forth the entire
agreement between the parties with respect to the subject matter contained
herein and supersedes any previous understandings, commitments or agreements,
whether oral or written, with respect to the subject matter contained herein.
This Agreement may only be amended with a writing signed by authorized
representatives of both parties hereto that specifically and expressly refers to
this Agreement. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR
ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM
RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT
(INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF
SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. If any provision
of this Agreement shall be found by a court to be void, invalid or
unenforceable, the same shall be reformed to comply with applicable law or
stricken if not so conformable, so as not to affect the validity or
enforceability of the remainder of this Agreement.

9.3 Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original, but both of which together shall constitute one and
the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this Agreement as of the Effective Date.

Steven M. Dell, M.D.                       eyeonics, inc

By: /s/ Steven M. Dell, M.D.               By: /s/ J. Andy Corley

                                           Name: J. Andy Corley

                                           Title: CEO

Address:1750 Far Gallant                   Addresss: 20970 AV Pkwy

           Austin, TX  78746               Aliso Viego

Facsimile:  512.328.8329                   Facsimile:

<PAGE>

                                    EXHIBIT A

                                LICENSED PATENTS

1.   Title: Floating Optic Accommodating Intraocular Lens (SD2). Applicant:
     Steven J. Dell. Patent No. 13533.4060

2.   Title: Floating Optic Accommodating Intraocular Lens (SD4). Applicant's: J.
     Stuart Cumming, Steven J. Dell, Jonathan R. Soiseth. Patent No. 13533.4063.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]